Glucose-stimulated expression of Txnip is mediated by carbohydrate response element-binding protein, p300, and histone H4 acetylation in pancreatic beta cells.
Recently, we identified Txnip (thioredoxin-interacting protein) as a mediator of glucotoxic beta cell death and discovered that lack of Txnip protects against streptozotocin- and obesity-induced diabetes by preventing beta cell apoptosis and preserving endogenous beta cell mass. Txnip has therefore become an attractive target for diabetes therapy, but although we have found that txnip transcription is highly induced by glucose through a unique carbohydrate response element, the factors controlling this effect have remained unknown. Using transient transfection experiments, we now show that overexpression of the carbohydrate response element-binding protein (ChREBP) transactivates the txnip promoter, whereas ChREBP knockdown by small interfering RNA completely blunts glucose-induced txnip transcription. Moreover, chromatin immunoprecipitation demonstrated that glucose leads to a dose- and time-dependent recruitment of ChREBP to the txnip promoter in vivo in INS-1 beta cells as well as human islets. Furthermore, we found that the co-activator and histone acetyltransferase p300 co-immunoprecipitates with ChREBP and also binds to the txnip promoter in response to glucose. Interestingly, this is associated with specific acetylation of histone H4 and recruitment of RNA polymerase II as measured by chromatin immunoprecipitation. Thus, with this study we have identified ChREBP as the transcription factor that mediates glucose-induced txnip expression in human islets and INS-1 beta cells and have characterized the chromatin modification associated with glucose-induced txnip transcription. In addition, the results reveal for the first time that ChREBP interacts with p300. This may explain how ChREBP induces H4 acetylation and sheds new light on glucose-mediated regulation of chromatin structure and transcription.
From the Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792; William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin 53705.
Hyunjoo
H
Cha-Molstad
From the Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792; William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin 53705.
Geetu
G
Saxena
From the Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792; William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin 53705.
Junqin
J
Chen
From the Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792; William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin 53705. Electronic address: as7@medicine.wisc.edu.
Anath
A
Shalev
D000818:Animals; D001665:Binding Sites / Q000235:genetics; D002352:Carrier Proteins / Q000235:genetics*; D018797:Cell Cycle Proteins; D002460:Cell Line; D006224:Cricetinae; D017362:Cyclic AMP Response Element-Binding Protein / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects; D005947:Glucose / Q000494:pharmacology; D006657:Histones / Q000378:metabolism; D006801:Humans; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D011401:Promoter Regions, Genetic / Q000187:drug effects; D051381:Rats; D014162:Transfection; D050880:p300-CBP Transcription Factors / Q000378:metabolism
D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D017362:Cyclic AMP Response Element-Binding Protein; D006657:Histones; C486715:TXNIP protein, human; C493796:TXNIP protein, rat; D050880:p300-CBP Transcription Factors; D005947:Glucose